Explore the words cloud of the REPO-TRIAL project. It provides you a very rough idea of what is the project "REPO-TRIAL" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||5˙536˙775 €|
|EC max contribution||5˙536˙772 € (100%)|
1. H2020-EU.3.1.5. (Methods and data)
|Duration (year-month-day)||from 2018-02-01 to 2023-01-31|
Take a look of project's partnership.
|1||UNIVERSITEIT MAASTRICHT||NL (MAASTRICHT)||coordinator||1˙270˙089.00|
|2||UNIVERSITY OF NEWCASTLE UPON TYNE||UK (NEWCASTLE UPON TYNE)||participant||844˙728.00|
|3||TECHNISCHE UNIVERSITAET MUENCHEN||DE (MUENCHEN)||participant||742˙045.00|
|4||UNIVERSITAETSKLINIKUM ESSEN||DE (ESSEN)||participant||597˙565.00|
|5||MEDIZINISCHE HOCHSCHULE HANNOVER||DE (HANNOVER)||participant||550˙722.00|
|6||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||participant||550˙722.00|
|7||Concentris Research Management GmbH||DE (Fürstenfeldbruck)||participant||355˙026.00|
|8||SOMALOGIC LIMITED||UK (CHOBHAM)||participant||342˙964.00|
|9||BIOCRATES LIFE SCIENCES AG||AT (INNSBRUCK)||participant||157˙789.00|
|10||MUCKE HERMANN||AT (WIEN)||participant||125˙122.00|
|11||SYDDANSK UNIVERSITET||DK (ODENSE M)||participant||0.00|
Our programme will develop an innovative in-silico based approach to improve the efficacy and precision of drug repurposing trials. We have chosen drug repurposing as it has the shortest time for clinical validation and translation. Validation of all putatively de novo discovered drug repositionings within the time-frame of this programme would be unrealistic. To improve efficacy and precision, and to adopt our computer simulation parameters and models, we choose a systems medicine based in-silico approach that identifies mechanistically related disease phenotypes and, as a result, a virtual patient cohort. We then validate this in-silico drug repurposing via high precision clinical trials in patients with cerebro-cardiovascular phenotypes stratified using an exclusive mechanistic biomarker panel. We thus innovate two biomedical product classes, drugs and diagnostics. With this we will establish generally applicable in silico trials for other mechanistically related or defined disease phenotypes, for which size, duration, and risks will be reduced and precision increased. This generates rapid patient benefit, reduces drug development costs as well as risks, and enhances industrial competitiveness. Scientifically, we will contribute to reducing the uncertainty and vagueness of many of our current disease definitions that describe a symptom or apparent phenotype in an organ rather than defining diseases mechanistically as disturbance of self-regulation equilibria of biomolecular processes. Finally, we will reduce animal experimentation and animal numbers in general by applying a preclinical randomised confirmatory trial (pRCTs) concept and preclinical systematic reviews and meta-analyses facilitated by our open access pre-clinicaltrials.org platform, a pendant to clinicaltrials.gov.
|Project brochure and professional templates||Websites, patent fillings, videos etc.||2019-11-06 13:06:26|
|Software for detection of pathway co-enrichment for extracting of patient(group)-specific pathways also enriched in target sites of effective drugs||Other||2019-11-06 13:06:20|
|Communication and dissemination plan||Websites, patent fillings, videos etc.||2019-11-06 13:06:11|
|Diseasome 2.0 network||Other||2019-11-06 13:06:12|
Take a look to the deliverables list in detail: detailed list of REPO-TRIAL deliverables.
|year||authors and title||journal||last update|
Mahmoud H. Elbatreek, Mayra P. Pachado, Antonio Cuadrado, Karin Jandeleit-Dahm, Harald H.H.W. Schmidt
Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage
published pages: 312-327, ISSN: 1043-2760, DOI: 10.1016/j.tem.2019.02.006
|Trends in Endocrinology & Metabolism 30/5||2019-09-26|
Ana I. Casas, Pamela W.M. Kleikers, Eva Geuss, Friederike Langhauser, Thure Adler, Dirk H. Busch, Valerie Gailus-Durner, Martin HrabÃª de Angelis, Javier Egea, Manuela G. Lopez, Christoph Kleinschnitz, Harald H.H.W. Schmidt
Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke
published pages: 1772-1778, ISSN: 0021-9738, DOI: 10.1172/jci124283
|Journal of Clinical Investigation 129/4||2019-09-26|
Ana I. Casas, Ahmed A. Hassan, Simon J. Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W. M. Kleikers, Emre Guney, Javier Egea, Manuela G. LÃ³pez, Jan Baumbach, Harald H. H. W. Schmidt
From single drug targets to synergistic network pharmacology in ischemic stroke
published pages: 7129-7136, ISSN: 0027-8424, DOI: 10.1073/pnas.1820799116
|Proceedings of the National Academy of Sciences 116/14||2019-09-26|
Joaquim Aguirre-Plans, Janet PiÃ±ero, JÃ¶rg Menche, Ferran Sanz, Laura Furlong, Harald Schmidt, Baldo Oliva, Emre Guney
Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology
published pages: 61, ISSN: 1424-8247, DOI: 10.3390/ph11030061
Simon J Larsen, Richard RÃ¶ttger, Harald HÂ HÂ W Schmidt, Jan Baumbach
E. coli gene regulatory networks are inconsistent with gene expression data
published pages: 85-92, ISSN: 0305-1048, DOI: 10.1093/nar/gky1176
|Nucleic Acids Research 47/1||2019-09-26|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REPO-TRIAL" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "REPO-TRIAL" are provided by the European Opendata Portal: CORDIS opendata.
Integrated and standardized NGS workflows for Personalised therapyRead More
A federated FAIR platform enabling large-scale analysis of high-value cohort data connecting Europe and Canada in personalized healthRead More
EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.Read More